A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

February 25, 2022

Study Completion Date

February 25, 2022

Conditions
Relapse/Refractory Multiple Myeloma
Interventions
DRUG

ATG-010

"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"

Trial Locations (17)

100020

Beijing Chao-Yang Hospital, Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

110004

Shengjing Hospital of China Medical University, Shenyang

130021

The First Bethune Hospital of Jilin University, Changchun

200003

Shanghai Changzheng Hospital, Shanghai

200233

Shanghai Sixth People's Hospital Affiliate Shanghai JiaoTong University, Shanghai

210029

The First Affilate Hospital with Nanjing Medical University, Nanjing

215006

The First Affiliated Hospital of Soochow University, Suzhou

300020

Tianjin blood research institute, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

The First Affiliated Hospital of Nanchang University, Nanchang

410013

The Third Xiangya Hospital of Central Suoth University, Changsha

450003

Henan Cancer Hospital, Zhengzhou

510000

Guangdong Provincial Peoples Hospital, Guangzhou

510060

Sun Yat-Sen University Cancer Center, Guanzhou

510515

Nanfang Hospital, Guangzhou

710032

Xijing Hospital, Xi’an

All Listed Sponsors
lead

Antengene Corporation

INDUSTRY

NCT03944057 - A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter